Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.41. Xtant Medical shares last traded at $0.37, with a volume of 541,085 shares traded.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 price target on Xtant Medical and gave the company a “buy” rating in a research note on Friday, October 18th.

Xtant Medical Price Performance

The stock has a market cap of $50.75 million, a PE ratio of -2.81 and a beta of 0.34. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings data on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $27.94 million during the quarter. Xtant Medical had a negative net margin of 15.45% and a negative return on equity of 37.07%.

Institutional Investors Weigh In On Xtant Medical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in Xtant Medical by 70.2% during the third quarter. Geode Capital Management LLC now owns 515,006 shares of the medical device company’s stock worth $348,000 after buying an additional 212,394 shares during the period. Evernest Financial Advisors LLC purchased a new position in shares of Xtant Medical during the third quarter worth approximately $27,000. Finally, Vanguard Group Inc. grew its position in shares of Xtant Medical by 3.2% during the first quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock worth $1,812,000 after acquiring an additional 48,319 shares during the last quarter. 69.33% of the stock is currently owned by institutional investors and hedge funds.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.